Markets:

Overview

News

Currencies

International

Treasuries

Global Blood Therapeutics, Inc. - Common Stock (NQ:GBT)

N/A UNCHANGED

Last Price Updated: 4:00 PM EDT, Oct 4, 2022 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Global Blood Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >

Biotech Stocks Well-Positioned For The Fourth Quarter ↗

October 12, 2022

The path of interest rates is clearer for 2022 and the FED is closer to a pause early next year as it calibrates its response from a hammer approach so far.

Via Talk Markets

These Were the Five Best And Worst Performing Mid-Cap Stocks In August 2022 ↗

September 20, 2022

We have used the August return data from finviz.com to come up with the five best and worst performing mid-cap stocks in August 2022.

Via Talk Markets

Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin ↗

September 15, 2022

The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.

Via Investor's Business Daily

Global Blood Therapeutics's Return On Capital Employed Overview ↗

September 15, 2022

Benzinga Pro data, Global Blood Therapeutics (NASDAQ:GBT) reported Q2 sales of $71.55 million. Earnings fell to a loss of $82.47 million, resulting in a 1.29% decrease from last quarter.

Via Benzinga

Where Global Blood Therapeutics Stands With Analysts ↗

August 09, 2022

Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:

Via Benzinga

Pfizer Inks $5.4 Billion Deal To Acquire Global Blood Therapeutics ↗

August 08, 2022

The deal adds to Pfizer's efforts to tackle sickle cell disease.

Via Investor's Business Daily

Pfizer Scoops Up Sickle Disease Player For $5B ↗

August 08, 2022

Via Benzinga

Global Blood Therapeutics's Return On Capital Employed Overview ↗

September 01, 2022

Global Blood Therapeutics (NASDAQ:GBT) brought in sales totaling $71.55 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 1.29%, resulting in a loss of $82.47...

Via Benzinga

After Pfizer, Now Novo Nordisk Beefs Up Its Sickle Cell Portfolio With Forma Therapeutics Deal ↗

September 01, 2022

Via Benzinga

GLOBAL BLOOD THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Global Blood Therapeutics, Inc. - GBT

August 31, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

10 Biotech Stocks Are Up 40% Or More This Year, Including Karuna, Axsome And Others ↗

August 29, 2022

These names are benefitting from M&A, clinical data and promising regulatory actions.

Via Investor's Business Daily

Blistering-Hot Biotech Shopping Spree Continues: Alcon To Buy Aerie For $770 Million ↗

August 23, 2022

The biopharma buying spree continued Tuesday with glaucoma drugs maker Aerie.

Via Investor's Business Daily

Stock Market Rally Rises On Inflation Data; Nvidia, Micron, Tesla, Disney In Focus: Weekly Review ↗

August 12, 2022

The major indexes continued to advance, despite some key warnings.

Via Investor's Business Daily

Analysts See Softened Timelines For CRISPR Therapeutics' Sickle Cell Candidate In US ↗

August 09, 2022

Via Benzinga

8 Analysts Have This to Say About Global Blood Therapeutics ↗

August 09, 2022

Within the last quarter, Global Blood Therapeutics (NASDAQ:GBT) has observed the following analyst ratings:

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2022 ↗

August 09, 2022

Via Benzinga

Global Blood Therapeutics: Q2 Earnings Insights ↗

August 08, 2022

Global Blood Therapeutics (NASDAQ:GBT) reported its Q2 earnings results on Monday, August 8, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

August 08, 2022

From Kahn Swick & Foti, LLC

Via Business Wire

Why These Pfizer Analysts Like The Global Blood Therapeutics Deal ↗

August 08, 2022

Pfizer Inc. (NYSE: PFE) shares were trading lower Monday after the drugmaker announced a $5.4-billion bid to acquire blood disorder drugmaker Global Blood Therapeutics Inc (NASDAQ: GBT).

Via Benzinga

TBLT, RDBX: The Top 5 Short Squeeze Stocks to Watch This Week ↗

August 08, 2022

Short squeeze stocks are still a hot topic this week and we're listing five of the shares investors will want to keep an eye on!

Via InvestorPlace

GBT Stock Alert: Pfizer Is Officially Acquiring Global Blood Therapeutics ↗

August 08, 2022

GBT stock is already rallying on takeover talk. Now that Pfizer has confirmed the buyout, Global Blood Therapeutics is red hot.

Via InvestorPlace

Benzinga's Top Ratings Upgrades, Downgrades For August 8, 2022 ↗

August 08, 2022

Via Benzinga

Global Blood (GBT) Stock Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Sale of Global Blood Therapeutics, Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – GBT

August 08, 2022

From Halper Sadeh LLP

Via Business Wire

Benzinga Before The Bell: Elon Musk Confirms Tesla AI Day Part 2, Dogecoin Scam, BioNTech Q2 Earnings Shocker And Other Top Financial Stories Monday, August 8 ↗

August 08, 2022

CNBC Celsius Withdraws Motion To Rehire CFO

Via Benzinga

iRobot, Fox Factory, TripAdvisor And Some Other Big Gainers From Friday ↗

August 08, 2022

U.S. stocks closed mixed on Friday following the release of jobs data for July. Here is the list of some big stocks moving higher in the previous session.

Via Benzinga

Why Quoin Pharmaceuticals Plunged Over 62%; Here Are 120 Biggest Movers From Friday ↗

August 08, 2022

Gainers

Via Benzinga

Small Cap Biotechs Perk Up On Dealmaking ↗

August 06, 2022

With M&A picking up we would think smaller deals make sense for large cap biopharma to expand pipelines and complement technology.

Via Talk Markets

12 Health Care Stocks Moving In Friday's Intraday Session ↗

August 05, 2022

Via Benzinga

A Preview Of Global Blood Therapeutics's Earnings ↗

August 05, 2022

Global Blood Therapeutics (NASDAQ:GBT) is set to give its latest quarterly earnings report on Monday, 2022-08-08. Here's what investors need to know before the announcement. Analysts estimate that...

Via Benzinga

Pfizer Is Reportedly In 'Advanced Talks' To Buy Global Blood Therapeutics For $5 Billion ↗

August 05, 2022

Shares of Pfizer's rumored takeover target have rocketed for two days running.

Via Investor's Business Daily

< Previous 1 2 3 4 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.